铁醇对二二甲引起的急性毒性对大鼠的影响
Mehmet Çömez1, Mustafa Cellat2, Müslüm Kuzu3
1Department of Anesthesiology and Reanimation, Faculty of Medicine, Hatay Mustafa Kemal University, Hatay, Turkey.
Journal of biochemical and molecular toxicology
|November 17, 2023
概括
提洛索尔的预处理可以防止迪克洛芬雅克引起的脏损伤. 这项研究表明,tyrosol.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 生物化学 生物化学
背景情况:
- 狄克洛菲纳克 (DCF) 是一种常见的NSAID,在长期使用或过量服用时可能会导致脏损伤.
- 了解DCF毒性机制对于制定保护策略至关重要.
研究的目的:
- 调查提洛索尔 (Tyr) 预处理对大鼠迪克洛菲纳克诱导的损伤的保护作用.
- 评估与DCF暴露和Tyr治疗相关的生化和组织病理变化.
主要方法:
- 32只老鼠被分为四组:对照组,DCF,DCF+Tyr和Tyr.
- 生物化学参数 (肌素,尿素,BUN,GSH,MDA,GPx,CAT) 和分子标记物 (COX-2,NF-κB,Tnf-α,Nrf-2,IL-1β) 进行了分析.
- 脏组织被用阴道病理学检查.
主要成果:
- 服用DCF会增加血清肌素,尿素和BUN以及脏MDA水平,同时降低GSH和GPx活性.
- DCF增加了COX-2,NF-κB和Tnf-α,并降低了Nrf-2水平.
- 铁醇预处理显著逆转了这些生化和分子变化,缓解了诸如管状退化和亡等组织病理损伤.
结论:
- 铁醇具有显著的保护作用,可以防止二二甲引起的毒性.
- 铁醇的保护机制涉及其抗炎和抗氧化特性,调节关键的氧化应激和炎症通路.
- 铁醇是一种潜在的治疗剂,可以预防NSAID相关的损伤.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Acute Kidney Injury IV: Diagnostic Studies and Prevention
18
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
18
Renal Failure: Dose Adjustments
95
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
95


